THE ROLE OF ENDOTHELIAL DYSFUNCTION IN THE DEVELOPMENT OF HEMOSTATIC DISTURBANCES IN RHEUMATOID ARTHRITIS AND IMPROVING TREATMENT STRATEGIES
Downloads
Objective: This article investigates the role of endothelial dysfunction in the development of hemostatic disturbances and cardiovascular complications in rheumatoid arthritis (RA) patients. It aims to understand how RA-induced inflammation leads to endothelial dysfunction, increasing oxidative stress, and disrupting the blood clotting system, which heightens the risk of thrombosis and cardiovascular diseases. Methods: The study reviews existing literature and current treatment strategies, including biological therapies, anticoagulants, and anti-inflammatory agents, to explore their impact on reducing endothelial dysfunction and improving cardiovascular outcomes in RA patients. Results: The findings demonstrate that endothelial dysfunction, as a result of RA-induced inflammation, contributes to oxidative stress and disturbances in the blood clotting system. These factors collectively elevate the risk of thrombosis and cardiovascular diseases in RA patients, which are leading causes of morbidity and mortality. Novelty: This article highlights emerging therapeutic approaches that may provide better management of endothelial dysfunction and hemostatic disturbances in RA, offering new potential strategies for improving patient outcomes beyond current treatment options.
H. Kitasato and T. Furuya, "Endothelial dysfunction and thrombosis in rheumatoid arthritis," Journal of Rheumatology, vol. 48, no. 7, pp. 1012-1020, 2021.
J. Smith and L. Garcia, "Mechanisms of inflammation in rheumatoid arthritis: Implications for therapy," Clinical Immunology, vol. 212, pp. 108-115, 2020.
X. Wang and H. Zhang, "The role of endothelial dysfunction in cardiovascular disease in rheumatoid arthritis," Cardiovascular Research, vol. 104, no. 3, pp. 561-569, 2019.
M. Malavolta and A. Santoro, "Biomarkers in the treatment of rheumatoid arthritis," Autoimmunity Reviews, vol. 17, no. 3, pp. 231-239, 2018.
A. Kavanaugh and A. Gottlieb, "Rheumatoid arthritis and cardiovascular risk," The Lancet, vol. 389, no. 10065, pp. 1552-1564, 2017.
X. Yu and M. Zhao, "Advanced therapeutic approaches in the management of rheumatoid arthritis: From DMARDs to biologics," Current Opinion in Rheumatology, vol. 34, no. 4, pp. 404-411, 2022.
J. Singh and R. Manek, "Endothelial dysfunction in autoimmune diseases: A review," International Journal of Rheumatology, vol. 2016, pp. 829-836, 2016.
K. Laing and W. Tan, "Oxidative stress and endothelial dysfunction in rheumatoid arthritis," European Journal of Clinical Investigation, vol. 45, no. 2, pp. 121-130, 2015.
M. Feldmann and R. Maini, "Biologic therapies in rheumatoid arthritis: Mechanisms of action," Rheumatology, vol. 58, no. 7, pp. 1019-1028, 2019.
R. Gibbons and D. Blankenhorn, "Endothelial dysfunction as a marker for cardiovascular risk in rheumatoid arthritis," American Heart Journal, vol. 161, no. 2, pp. 320-327, 2018.
Copyright (c) 2025 Musayeva Nargiza Baxtiyorovna

This work is licensed under a Creative Commons Attribution 4.0 International License.














